Supplementary Figure 2 from Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

MLA

Fei Su, et al. Supplementary Figure 2 from Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer. Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4972aa2417a75198749ee7ce578cb397&authtype=sso&custid=ns315887.

APA

Fei Su, Gideon Bollag, Brian Lestini, David Heimbrook, Scott Kopetz, Mary Ellen Simcox, Kathleen Schostack, Richard J. Lee, William D. Bradley, Kathryn Packman, Kenneth Kolinsky, Brian Higgins, & Hong Yang. (2023). Supplementary Figure 2 from Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer.

Chicago

Fei Su, Gideon Bollag, Brian Lestini, David Heimbrook, Scott Kopetz, Mary Ellen Simcox, Kathleen Schostack, et al. 2023. “Supplementary Figure 2 from Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4972aa2417a75198749ee7ce578cb397&authtype=sso&custid=ns315887.